Section Sub-head
Header
Sub-head
Header
Sub-head
-
Recor Medical Announces AMA CPT Editorial Panel Approval of Two New Category I CPT® Codes for Renal Denervation
Palo Alto, Calif. – October 2, 2026 – Recor Medical, Inc. (“Recor”), a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., today announced that the American Medical Association (AMA) Current Procedural Terminology (CPT) Editorial Panel created two Category I CPT codes describing renal denervation.
-
Recor Medical Names Dr. Helen Reeve-Stoffer Chief Executive Officer
Palo Alto, Calif. – August 4, 2026 – Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) have appointed Helen Reeve-Stoffer, PhD, President and Chief Executive Officer. Dr. Helen Reeve-Stoffer, who most recently served as Chief Operating Officer, will lead continued global development and commercialization of the company’s Paradise™ Ultrasound Renal Denervation system for the treatment of uncontrolled hypertension.
-
Recor Medical Highlights Innovation and Global Action on World Hypertension Day 2026
Palo Alto, CA, USA – May 15, 2026 – In recognition of World Hypertension Day 2026, taking place on Sunday, May 17, Recor Medical, Inc. (“Recor”), a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., joins the global community in raising awareness of high blood pressure and celebrating the progress being made in its…
-
Recor Medical’s Paradise Ultrasound Renal Denervation System Honored with TAG Award for Cardiovascular Therapeutic Innovation
Palo Alto, Calif. – April 22, 2026 – Recor Medical, Inc. (“Recor”), a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., today announced that the Paradise™ Ultrasound Renal Denervation (uRDN) system has been recognized with a TAG award in the Medical Devices: Cardiovascular Therapeutic Innovation category. The award was presented at the Medical Design & Manufacturing (MD&M)…
-
Paradise Ultrasound Renal Denervation System for the Treatment of Resistant Hypertension, Now Covered by Insurance and Commercially Available in Japan
Otsuka Medical Devices Co., Ltd. (Otsuka Medical Devices) and Otsuka Pharmaceutical Co., Ltd. (Otsuka Pharmaceutical) announce that the Paradise™ Ultrasound Renal Denervation (uRDN) system is covered by National Health Insurance system in Japan, effective March 1. Following the inception of insurance coverage, Otsuka Medical Devices has commenced sales of the system on March 2 and…
-
Latest Real-World Clinical Data Demonstrate a 19.6 mmHg Reduction in Blood Pressure at 6 Months with Recor Medical’s Paradise Ultrasound Renal Denervation System
Palo Alto, Calif. – October 30, 2025 – Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), today announced results from two clinical studies presented at the 2025 Transcatheter Cardiovascular Therapeutics (TCT) conference this week: data from the Global Paradise System (GPS) Registry demonstrated a 19.6 mmHg reduction in office systolic blood…